Ivabrad
Ivabrad is ivabradine 7.5 mg tablets — the first selective I-f current inhibitor, acting at the sinoatrial node to slow heart rate without affecting blood pressure, contractility, or AV conduction. Originally Servier Procoralan (2005). SHIFT trial validated in HF-REF with HR >70 despite beta-blocker; BEAUTIFUL/SIGNIFY extended evidence to chronic stable angina. Only effective in sinus rhythm — not for atrial fibrillation. Contraindicated with strong CYP3A4 inhibitors.
✓ Lääketieteellinen tarkistus Morgan Ellis — Farmasian tutkija · 8 vuoden kokemus · Viimeisin arvio: toukokuu 2026
⚡ Quick Answer — What is Ivabrad?
Ivabrad is 7.5 mg ivabradine tablets from a WHO-GMP certified manufacturer — a selective inhibitor of the If (“funny”) current in the sinoatrial node. Ivabradine was introduced by Servier in 2005 as Procoralan — the first drug to selectively slow heart rate without affecting blood pressure, myocardial contractility, or other ion channels. Targets the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that generate the If current responsible for spontaneous SA node depolarisation. selectively blocks If in the sinoatrial node, reducing the slope of spontaneous diastolic depolarisation and slowing heart rate. Unlike beta-blockers and non-DHP CCBs, ivabradine has no effect on cardiac contractility, BP, or AV node conduction — it is a “pure” bradycardia agent. Dosing: Start 5 mg twice daily with food; titrate to 7.5 mg twice daily at 2 weeks if resting HR >60 bpm and tolerated. Reduce to 2.5 mg twice daily if HR falls below 50 bpm or symptoms develop. In elderly (>75 yr) start 2.5 mg twice daily. Arrhythmia management is a cardiology-led discipline — diagnosis, drug selection, and monitoring typically require specialist input. This is not a drug for self-initiated therapy.
📦 Jokainen tilaus on katettuna meidän Reshipment Assurance Policy -politiikkamme piiriin — jos lähetyksesi ei saavu 20 arkipäivässä, lähetämme uuden.
Miksi tilata MedsBasesta
Geneeriset lääkkeemme on hankittu WHO-GMP sertifioiduilta valmistajilta ja toimitettu maailmanlaajuisesti hienotunteisessa, neutraalissa pakkauksessa — lääkkeen nimeä ei ole pakkauksen ulkopuolella. Korttimaksut käsitellään säädeltyjen maksunvälittäjien kautta (tilisiirtojen kuvaukset sisältävät säädellyn korttimaksun käsittelijän — ei koskaan “MedsBase” tai lääkkeen nimeä). Kryptovaluutat ja SEPA-pankkisiirrot hyväksytään myös. Jokainen tilaus on turvattu meidän Reshipment Assurance Policy -takuuohjelmalla.
What Is Ivabrad?
Ivabrad is 7.5 mg ivabradine tablets from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Ivabradine was introduced by Servier in 2005 as Procoralan — the first drug to selectively slow heart rate without affecting blood pressure, myocardial contractility, or other ion channels. Targets the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that generate the If current responsible for spontaneous SA node depolarisation.
How Ivabradine Works
Ivabradine selectively blocks If in the sinoatrial node, reducing the slope of spontaneous diastolic depolarisation and slowing heart rate. Unlike beta-blockers and non-DHP CCBs, ivabradine has no effect on cardiac contractility, BP, or AV node conduction — it is a “pure” bradycardia agent.
Hyväksyttyjä käyttökohteita
- Chronic symptomatic heart failure with reduced ejection fraction (HF-REF) — in patients with EF ≤35%, sinus rhythm, and heart rate >70 bpm despite maximum-tolerated beta-blocker (or beta-blocker intolerance). SHIFT trial evidence.
- Krooninen vakaa angina — add-on to beta-blocker or alone where beta-blockers are contraindicated. BEAUTIFUL and SIGNIFY trials.
- Inappropriate sinus tachycardia (off-label)
Annostelu ja seuranta
Annostelu: Start 5 mg twice daily with food; titrate to 7.5 mg twice daily at 2 weeks if resting HR >60 bpm and tolerated. Reduce to 2.5 mg twice daily if HR falls below 50 bpm or symptoms develop. In elderly (>75 yr) start 2.5 mg twice daily.
Seuranta:
- Alkutilanne: 12-lead ECG (confirm sinus rhythm, assess HR and QT), BP, U&E.
- 2-4 weeks: HR review; titrate up or down.
- Jatkuva: periodic HR and ECG; target resting HR 50-60 bpm in HF-REF.
- Lopeta seuraavissa tapauksissa: symptomatic bradycardia (HR <50 with symptoms), new AF (ivabradine efficacy is sinus-rhythm dependent), visual phenomena severe enough to affect driving/work.
Haittavaikutukset
- Luminous phenomena (phosphenes) — transient enhanced brightness in peripheral vision (15%); usually improves spontaneously. Mechanism: ivabradine also weakly blocks Ih current in retinal photoreceptors.
- Bradykardia — dose-limiting (5-10%)
- Eteisvärinä — modest excess vs placebo in trials; the drug is not effective once sinus rhythm is lost
- Päänsärky, huimaus
- First-degree AV block, ventricular extrasystoles
- Iho-oireet
Käyttökiellot
- Resting HR <70 bpm before starting
- Cardiogenic shock, acute MI
- Vakava hypotensio
- Sick sinus syndrome, sinoatrial block, third-degree AV block without pacemaker
- Unstable or acute heart failure
- Atrial fibrillation (not effective; may worsen rate control)
- Pacemaker-dependent
- Vakava maksatoimintavajaus
- Strong CYP3A4 inhibitor co-therapy
- Raskaus ja imetys
Lääkeaineenvaihdunta
- Voimakkaat CYP3A4-estäjät — KRIITTINEN. Contraindicated: clarithromycin, itraconazole, ketoconazole, ritonavir, nefazodone, nelfinavir. Caution with moderate inhibitors (diltiazem, verapamil — note these also add bradycardia independently).
- Diltiazem, verapamil — avoid (additive bradycardia + CYP3A4 inhibition).
- QT-aikaa pidentävät lääkeaineet — caution; ivabradine has minimal intrinsic QT effect but combined risk rises.
- Greippimehu — raises ivabradine levels.
- Beetalohentajat — combination is standard in HF-REF where beta-blocker alone is inadequate; watch for additive bradycardia.
Usein Kysytyt Kysymykset
What are the visual phosphenes?
About 15% of patients experience transient enhanced brightness in peripheral vision — particularly when looking from dim to bright light. They are benign (ivabradine weakly blocks a similar current in retinal photoreceptors) and usually adapt over weeks. Severe phenomena that affect driving or work are indication to stop.
Can I take ivabradine if I have atrial fibrillation?
No — ivabradine only slows the sinoatrial node, so it has no effect on AF and may even make rate control worse. In AF use beta-blockers, non-DHP CCBs, or digoxin instead.
Can I take Ivabrad in pregnancy?
Generally no. Ivabradine has animal teratogenicity data; pregnancy is contraindicated in the licensed indications.
Where can I buy Ivabrad online?
You can buy Ivabrad (ivabradine 7.5 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.
Aiheeseen liittyvät sydän- ja verisuonilääkkeet
- Abana — ayurvedalainen sydänlääkevalmiste
- Aldactone — Spironolaktoni
- Cardace — Ramipriili (ACE-estäjä)
- Ecosprin — Aspiriini 75/150 mg (verenhyytymisen estäjä)
- Lonitab — Minoksidiili 5 mg (suun kautta nautittava verisuonia laajentava lääke)
- Vymada — Sacubitril/Valsartan ARNI
- Selaa kaikkia verenpainelääkkeitä
Aiheeseen liittyvät vaihtoehdot
Muut tuotteet Krooniset sairaudet joita asiakkaat myös katsovat:
Hinta-alue: 9,00 USD - 36,00 USD
Luokiteltu MedsBase-tilausmäärän mukaan — mitä muut asiakkaat tässä kategoriassa valitsevat.
| Vahvuus | 7.5 mg |
|---|---|
| Määrä | 30 tablettia, 60 tablettia, 90 tablettia, 180 tablettia |
Ivabrad
Kysymykset ja vastaukset
Ivabrad
Liittyvät tuotteet
Arvostelut
Ei vielä arvosteluja